Introduction
The advent of antiretroviral therapy (ART) has transitioned HIV infection from a terminal illness to a manageable chronic condition. However, long-term ART is frequently associated with metabolic complications, including dyslipidemia and altered purine metabolism. The regimen consisting of Tenofovir (TDF), Lamivudine (3TC), and Efavirenz (EFV) is a standard first-line treatment in many global health programs. While its efficacy in viral suppression is well-documented, its long-term impact on lipid profiles requires deeper investigation. This study evaluates the metabolic health of HIV-positive male patients over a 144-week period.
Methodology
This prospective cohort study followed 61 treatment-naive male patients at the Public and Health Clinical Center of Chengdu, China. Participants were categorized into three groups based on their baseline CD4+ T cell counts: <200, 200–350, and >350 cells/µl. All patients received the TDF+3TC+EFV regimen. Metabolic parameters, including Total Cholesterol (TC), Triglycerides (TG), LDL-c, HDL-c, and Uric Acid (UA), were monitored at baseline and at 12 subsequent intervals up to week 144. Statistical analysis utilized one-way ANOVA and multiple stepwise regression to identify predictors of metabolic shifts.
Results
Lipid Profile Evolution
The study observed a progressive increase in lipid levels over the 144-week follow-up. Total Cholesterol (TC) rose significantly from a baseline mean of 4.20 mmol/L to 4.67 mmol/L (P=0.001). Similarly, HDL-c levels showed a significant upward trend (P<0.001). While TG and LDL-c levels also increased, these changes did not reach statistical significance.
Impact of Baseline Immune Status
Baseline CD4+ T cell counts were found to influence initial lipid levels. Patients with lower baseline CD4+ counts (<200 cells/µl) generally exhibited higher TG levels and lower TC, LDL-c, and HDL-c levels at the start of therapy. Over time, the prevalence of hypercholesterolemia increased from 24.59% to 50.00%, while the prevalence of low HDL-c decreased significantly from 36.07% to 7.14%.
Predictors of Metabolic Change
Regression analysis identified age, body weight, and the duration of follow-up as the primary drivers for increases in TC and TG. Interestingly, uric acid levels remained relatively stable and were more closely associated with viral load than with the duration of ART.
Discussion
The findings suggest that the "return to health" phenomenon—where lipid levels rise as the body recovers from HIV-induced wasting—may transition into a long-term risk for cardiovascular disease. The continuous rise in cholesterol levels beyond the initial recovery phase highlights the need for persistent monitoring. The correlation between body weight/fat and lipid levels underscores the importance of lifestyle management alongside pharmacological treatment.
Conclusion
While the TDF+3TC+EFV regimen is effective for viral control, it is associated with a gradual increase in dyslipidemia. Clinicians should prioritize long-term monitoring of lipid metabolism and consider early interventions to mitigate cardiovascular risks in patients undergoing prolonged ART.
Summary updated